Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworksJournal of Psychopharmacology · 2026-08-17Processing Intergenerational Trauma With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-08-13The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderClinicalTrials.gov · 2026-08-13TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-08-12A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety DisorderClinicalTrials.gov · 2026-08-12Effects of Psilocybin in Patients With Amyotrophic Lateral SclerosisClinicalTrials.gov · 2026-08-11A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced CancerClinicalTrials.gov · 2026-08-05Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-08-03A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionClinicalTrials.gov · 2026-07-30Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-07-30Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-07-30An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSDClinicalTrials.gov · 2026-07-29Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND)ClinicalTrials.gov · 2026-07-23Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-07-21PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)ClinicalTrials.gov · 2026-07-07A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-07-01Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-26Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23Psilocybin-Assisted Therapy for Prolonged GriefClinicalTrials.gov · 2026-06-23Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.Clinical toxicology (Philadelphia, Pa.) · 2026-06-23Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05Therapeutic advances in fibromyalgia: one year in review 2026.Clinical and experimental rheumatology · 2026-06-01Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headacheJournal of Psychopharmacology · 2026-05-29Group Psilocybin-Assisted Therapy for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-05-22A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for DepressionClinicalTrials.gov · 2026-05-20Psilocybin-assisted Cognitive Behavioral Therapy for DepressionClinicalTrials.gov · 2026-05-19Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)ClinicalTrials.gov · 2026-05-14Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleClinicalTrials.gov · 2026-05-12A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With CancerClinicalTrials.gov · 2026-05-06Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive DisorderClinicalTrials.gov · 2026-05-04Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in RemissionClinicalTrials.gov · 2026-04-21Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use DisorderClinicalTrials.gov · 2026-04-07Pilot Study of Psilocybin-assisted Treatment for Cannabis Use DisorderClinicalTrials.gov · 2026-03-18Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot StudyClinicalTrials.gov · 2026-03-18A fungus among us: investigating queensland’s largest magic mushroom growing operationAustralian Journal of Forensic Sciences · 2026-03-16Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's DiseaseClinicalTrials.gov · 2026-03-16Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-03-04Study of Psilocybin for Anorexia in Young AdultsClinicalTrials.gov · 2026-03-03Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse PreventionAddiction Biology · 2026-03-01Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH StudyClinicalTrials.gov · 2026-02-17The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing TraumaClinicalTrials.gov · 2026-01-22Psilocybin and ibogaine as therapeutic candidates for cocaine addiction: Insights from a rat self-administration modelNeuroscience Applied · 2026-01-01The Effect of on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress.Journal of psychoactive drugs · 2026-01-01Marketing by online tobacco retailers: An observational cross-sectional study.Tobacco induced diseases · 2026-01-01Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.Journal of clinical psychopharmacology · 2026-01-01The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationClinicalTrials.gov · 2025-12-24An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality DisorderClinicalTrials.gov · 2025-12-23Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterClinicalTrials.gov · 2025-12-22Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility StudyClinicalTrials.gov · 2025-12-04[Psilocybin in the setting of treatment-resistant unipolar depression: A case report].L'Encephale · 2025-12-01Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.Molecular psychiatry · 2025-12-01Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.Molecular psychiatry · 2025-12-01Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic CancerClinicalTrials.gov · 2025-11-05Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.Molecular neurobiology · 2025-11-01Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older AdultsClinicalTrials.gov · 2025-10-21A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic CancerClinicalTrials.gov · 2025-10-14A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From MethamphetamineClinicalTrials.gov · 2025-10-07Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.Progress in neuro-psychopharmacology & biological psychiatry · 2025-10-02Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathwayNaunyn-Schmiedeberg's Archives of Pharmacology · 2025-10-01S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19PRoMiSS: Psilocybin and the Role of Music in Set and SettingClinicalTrials.gov · 2025-09-18The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.ClinicalTrials.gov · 2025-09-15Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.Journal of psychopharmacology (Oxford, England) · 2025-09-01Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic SeizuresClinicalTrials.gov · 2025-08-21Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging StudyClinicalTrials.gov · 2025-08-20Effects of Psilocybin in Post-Treatment Lyme DiseaseClinicalTrials.gov · 2025-08-20363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIORThe international journal of neuropsychopharmacology · 2025-08-01Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.The Journal of law, medicine & ethics: a journal of the American Society of Law, Medicine & Ethics · 2025-07-31The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)ClinicalTrials.gov · 2025-07-23The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping ReviewPreprints.org · 2025-06-19The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderClinicalTrials.gov · 2025-06-13Psilocybin With Intracranial Neural SensingClinicalTrials.gov · 2025-06-06Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility StudyClinicalTrials.gov · 2025-06-05The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.Neuroscience and biobehavioral reviews · 2025-05-01Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.Journal of psychoactive drugs · 2025-04-25A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With FibromyalgiaClinicalTrials.gov · 2025-04-16The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy TrainingClinicalTrials.gov · 2025-04-14Psilocybin-assisted Interpersonal Therapy for DepressionClinicalTrials.gov · 2025-04-09Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine PathwaysPharmacology Research & Perspectives · 2025-04-01Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey.Progress in neuro-psychopharmacology & biological psychiatry · 2025-03-20An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept StudyClinicalTrials.gov · 2025-03-19Effects of Psilocybin in Advanced-Stage Cancer Patients With AnxietyClinicalTrials.gov · 2025-03-13A qualitative analysis of the psychedelic mushroom come-up and come-down.Npj mental health research · 2025-02-07Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot StudyClinicalTrials.gov · 2025-01-01Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2025-01-01Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.Cureus · 2025-01-01Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.Cureus · 2025-01-01Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care.Palliative medicine reports · 2025-01-01Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybinbioRxiv · 2024-12-13A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating DisorderClinicalTrials.gov · 2024-11-19PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)ClinicalTrials.gov · 2024-11-06What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study.Palliative & supportive care · 2024-10-01An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II DisorderClinicalTrials.gov · 2024-09-25Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic FocusClinicalTrials.gov · 2024-09-19An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)ClinicalTrials.gov · 2024-08-09Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithiumbioRxiv · 2024-08-09Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility StudyClinicalTrials.gov · 2024-07-12The trajectory of psychedelic, spiritual, and psychotic experiences: implications for cognitive scientific perspectives on religionReligion Brain & Behavior · 2024-07-11Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First RespondersClinicalTrials.gov · 2024-06-24Psilocybin as a Treatment for Anorexia Nervosa: A Pilot StudyClinicalTrials.gov · 2024-06-17An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult PatientsClinicalTrials.gov · 2024-05-08EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2024-05-04Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.Psychiatry research · 2024-05-01A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With CancerClinicalTrials.gov · 2024-03-20Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.Med (New York, N.Y.) · 2024-03-08Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.Journal of psychopharmacology (Oxford, England) · 2024-03-01The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s JourneyResearch Square · 2024-02-23Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey.Palliative medicine · 2024-02-01The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDClinicalTrials.gov · 2024-01-24Effects of psilocybin and sleep quality on brain water diffusivity and microstructure in healthy individuals and chronic cluster headache patientsNeuroscience Applied · 2024-01-01When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research.Neuroethics · 2024-01-01Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities.Biotechnology progress · 2024-01-01The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-11-09Effects and Therapeutic Potential of Psilocybin in Alcohol DependenceClinicalTrials.gov · 2023-09-26Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted ConditionsClinicalTrials.gov · 2023-09-13"Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli".Biotechnology and bioengineering · 2023-08-01An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.ClinicalTrials.gov · 2023-07-25Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)ClinicalTrials.gov · 2023-07-06Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderClinicalTrials.gov · 2023-06-29Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military VeteransClinicalTrials.gov · 2023-05-25Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult VolunteersClinicalTrials.gov · 2023-05-19A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral PsilocybinClinicalTrials.gov · 2023-05-15Effects of Psilocybin in Anorexia NervosaClinicalTrials.gov · 2023-05-06Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyClinicalTrials.gov · 2023-03-20Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderClinicalTrials.gov · 2023-03-13SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for DepressionClinicalTrials.gov · 2023-01-30The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023-01-01History of the administration of psychedelics in France.Frontiers in psychology · 2023-01-01A Review of Synthetic Access to Therapeutic Compounds Extracted from.Pharmaceuticals (Basel, Switzerland) · 2022-12-28NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System.ClinicalTrials.gov · 2022-11-165-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in micebioRxiv · 2022-11-03The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.ClinicalTrials.gov · 2022-10-25An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)ClinicalTrials.gov · 2022-10-12Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review.Current psychiatry reports · 2022-10-01Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging StudyClinicalTrials.gov · 2022-08-10Evaluation of Psilocybin in Anorexia Nervosa: Safety and EfficacyClinicalTrials.gov · 2022-07-25Psilocybine vergeleken met escitalopram bij depressiePure Amsterdam UMC · 2022-01-17[Psilocybin compared with escitalopram for depression].Nederlands tijdschrift voor geneeskunde · 2022-01-17Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental HealthClinicalTrials.gov · 2021-12-16The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive DisorderClinicalTrials.gov · 2021-10-15Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case studyAnnales Médico-psychologiques revue psychiatrique · 2021-09-28Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experienceEuropean Neuropsychopharmacology · 2021-09-01Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS SurvivorsClinicalTrials.gov · 2021-01-07Psychedelics and Psychedelic-Assisted Psychotherapy.Focus (American Psychiatric Publishing) · 2021-01-01Snapshot of narcotic drugs and psychoactive substances in Kuwait: a qualitative analysis of illicit drugs and their associated mortality in Kuwait from 2015 to 2018Research Square · 2020-11-18Molecular docking and binding interaction between psychedelic drugs and human serum albuminBiotechnologia · 2020-06-16Psychedelics and Psychedelic-Assisted Psychotherapy.The American journal of psychiatry · 2020-05-01Pharmacokinetics of Psilocybin in Normal Adult VolunteersClinicalTrials.gov · 2020-04-15Measurement of Persisting Changes in Emotional Brain Functioning Produced by PsilocybinClinicalTrials.gov · 2019-09-10Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.Journal of affective disorders · 2018-04-01Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.Psychopharmacology · 2018-02-01[Student's use of illicit drugs: a survey in a preventive health service].L'Encephale · 2009-12-01[Psilocybin, a new hallucinogen].Ceskoslovenska psychiatrie · 1960-02-01